Results preview: Year 2017

Miércoles, 28 Febrero 2018.

Reig Jofre closes 2017 with an increase in sales of 4.3% in a year marked by the growth of its traditional business units and a significant recovery of the antibiotics and nutritional supplements product lines

  • The good performance of the two business units of Reig Jofre in the last quarter (areas of technological- and therapeutic specialization) allowed to achieve annual sales growth of 4.3% and set the turnover at € 168M, (total income of € 170M)
  • The continuous good evolution of injectables, dermatology and respiratory/ENT was complemented with the correction over the last quarter of the decrease in sales of the nutritional supplements line in France and antibiotics
  • The company increased personnel expenses by 7% and operating expenses by 6%, due to the reinforcement of the productive and R&D structures for the ongoing investments. Despite this, EBITDA maintained a positive evolution of 0.6% compared to 2016 and stood at € 15.8M
  • Net result grew by 14.9% compared to 2016 and reached € 8.8M, partly due to the favorable fiscal impacts for higher deductions in R&D and the partial reversal of the negative effect of tax credit deterioration in the previous year
  • The company improved its treasury position by reducing € 11M its net financial debt, which stood at € 18.3M, a debt/EBITDA ratio of 1.2 times compared to 1.8 times in 2016

Download the full document (PDF)

Esta web utiliza exclusivamente cookies técnicas de terceros para ofrecer un mejor servicio, al navegar por esta web aceptas su uso. Consulta nuestraaviso legal y política de cookies. Aceptar

Our website is protected by DMC Firewall!